EP4098262A4 - Pharmazeutische zusammensetzung zur vorbeugung oder behandlung von diabetes und damit verbundenen stoffwechselerkrankungen - Google Patents

Pharmazeutische zusammensetzung zur vorbeugung oder behandlung von diabetes und damit verbundenen stoffwechselerkrankungen Download PDF

Info

Publication number
EP4098262A4
EP4098262A4 EP21768861.3A EP21768861A EP4098262A4 EP 4098262 A4 EP4098262 A4 EP 4098262A4 EP 21768861 A EP21768861 A EP 21768861A EP 4098262 A4 EP4098262 A4 EP 4098262A4
Authority
EP
European Patent Office
Prior art keywords
diabetes
prevention
treatment
pharmaceutical composition
associated therewith
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21768861.3A
Other languages
English (en)
French (fr)
Other versions
EP4098262A1 (de
Inventor
Mi-Kyung Kim
Tae Hyoung Kim
Il Hoon Jung
Yu Na Chae
Jae Sung Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dong A ST Co Ltd
Dong-A ST Co Ltd
Original Assignee
Dong A ST Co Ltd
Dong-A ST Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong A ST Co Ltd, Dong-A ST Co Ltd filed Critical Dong A ST Co Ltd
Publication of EP4098262A1 publication Critical patent/EP4098262A1/de
Publication of EP4098262A4 publication Critical patent/EP4098262A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP21768861.3A 2020-03-11 2021-03-10 Pharmazeutische zusammensetzung zur vorbeugung oder behandlung von diabetes und damit verbundenen stoffwechselerkrankungen Pending EP4098262A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200030424 2020-03-11
PCT/KR2021/002990 WO2021182877A1 (ko) 2020-03-11 2021-03-10 당뇨 및 이에 동반하는 대사 질환의 예방 또는 치료를 위한 약학적 조성물

Publications (2)

Publication Number Publication Date
EP4098262A1 EP4098262A1 (de) 2022-12-07
EP4098262A4 true EP4098262A4 (de) 2024-02-28

Family

ID=77671854

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21768861.3A Pending EP4098262A4 (de) 2020-03-11 2021-03-10 Pharmazeutische zusammensetzung zur vorbeugung oder behandlung von diabetes und damit verbundenen stoffwechselerkrankungen

Country Status (11)

Country Link
US (1) US20230143119A1 (de)
EP (1) EP4098262A4 (de)
JP (1) JP7446465B2 (de)
KR (1) KR102538048B1 (de)
CN (1) CN115243689A (de)
AU (1) AU2021235294B2 (de)
BR (1) BR112022017942A2 (de)
CA (1) CA3167630A1 (de)
IL (1) IL295948B1 (de)
MX (1) MX2022011129A (de)
WO (1) WO2021182877A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102295300B1 (ko) 2018-09-12 2021-08-30 동아에스티 주식회사 Gpr119 리간드를 유효성분으로 포함하는 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016068453A1 (en) * 2014-10-27 2016-05-06 Dong-A St Co., Ltd. Compound having gpr119 agonistic activity, method for preparing the same, and pharmaceutical composition including the same as effective component
WO2017106112A1 (en) * 2015-12-16 2017-06-22 Merck Sharp & Dohme Corp. Methods of preventing or treating hypoglycemia by administering a gpr119 agonist
EP3827829A1 (de) * 2018-09-12 2021-06-02 Dong-A ST Co., Ltd. Pharmazeutische zusammensetzung mit gpr119-liganden als wirkstoff zur vorbeugung oder behandlung von nichtalkoholischer fettlebererkrankung

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2006000008A (es) * 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
UA91698C2 (ru) * 2005-01-10 2010-08-25 Арена Фармасьютікалз, Інк. Комбинированная терапия для лечения диабета и родственных ему состояний и для лечения состояний, улучшенных увеличением уровня glp-1 крови
WO2008130584A1 (en) * 2007-04-20 2008-10-30 Schering Corporation Pyrimidinone derivatives and methods of use thereof
US20120053180A1 (en) * 2010-08-27 2012-03-01 Chemizon, A Division Of Optomagic Co., Ltd. Cyclohexane analogues as gpr119 agonists
WO2012145604A1 (en) * 2011-04-22 2012-10-26 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
TW201625670A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
KR101726819B1 (ko) * 2014-10-27 2017-04-13 동아에스티 주식회사 Gpr119 작용 활성을 갖는 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016068453A1 (en) * 2014-10-27 2016-05-06 Dong-A St Co., Ltd. Compound having gpr119 agonistic activity, method for preparing the same, and pharmaceutical composition including the same as effective component
WO2017106112A1 (en) * 2015-12-16 2017-06-22 Merck Sharp & Dohme Corp. Methods of preventing or treating hypoglycemia by administering a gpr119 agonist
EP3827829A1 (de) * 2018-09-12 2021-06-02 Dong-A ST Co., Ltd. Pharmazeutische zusammensetzung mit gpr119-liganden als wirkstoff zur vorbeugung oder behandlung von nichtalkoholischer fettlebererkrankung

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BAHIRAT UMAKANT ASHOK ET AL: "Combination of APD668, a G protein-coupled receptor 119 agonist with linagliptin, a DPPIV inhibitor, prevents progression of steatohepatitis in a murine model of non-alcoholic steatohepatitis with diabetes", MEDICAL MOLECULAR MORPHOLOGY, SPRINGER JAPAN, TOKYO, vol. 52, no. 1, 29 June 2018 (2018-06-29), pages 36 - 43, XP036714731, ISSN: 1860-1480, [retrieved on 20180629], DOI: 10.1007/S00795-018-0200-4 *
DONG-A ST CO. ET AL: "A Study To Evaluate The Safety,Tolerability, PK and PD Of DA-1241 In Healthy Male Subjects | ClinicalTrials.gov", NCT03061981, 11 October 2017 (2017-10-11), pages 1 - 11, XP093120335, Retrieved from the Internet <URL:https://clinicaltrials.gov/study/NCT03061981> [retrieved on 20240116] *
See also references of WO2021182877A1 *

Also Published As

Publication number Publication date
JP7446465B2 (ja) 2024-03-08
AU2021235294A1 (en) 2022-09-08
AU2021235294B2 (en) 2024-05-30
NZ791224A (en) 2025-05-02
EP4098262A1 (de) 2022-12-07
IL295948A (en) 2022-10-01
US20230143119A1 (en) 2023-05-11
WO2021182877A1 (ko) 2021-09-16
CN115243689A (zh) 2022-10-25
KR20210114888A (ko) 2021-09-24
MX2022011129A (es) 2022-10-13
CA3167630A1 (en) 2021-09-16
JP2023517612A (ja) 2023-04-26
BR112022017942A2 (pt) 2023-01-17
KR102538048B1 (ko) 2023-05-30
IL295948B1 (en) 2026-04-01

Similar Documents

Publication Publication Date Title
EP3920889A4 (de) Telomerasehaltige exosomen zur behandlung von krankheiten im zusammenhang mit altersbedingter organdysfunktion
EP3498279A4 (de) Pharmazeutische zusammensetzung mit amodiaquin und antidiabetischem arzneimittel als wirkstoff zur prävention oder behandlung von diabetes
EP3934646A4 (de) Pharmazeutische zusammensetzungen zur behandlung von augenkrankheiten oder -leiden
EP3976059A4 (de) Behandlung von mit angiopoietin-like 7 (angptl7) assoziierten krankheiten
MA56047A (fr) Composés et compositions destinés au traitement d&#39;états pathologiques associés à une activité de sting
MA53193A (fr) Vidofludimus à utiliser dans le traitement ou la prévention de maladies virales
EP3753557A4 (de) Präventives oder therapeutisches mittel und pharmazeutische zusammensetzung für entzündungserkrankungen oder knochenerkrankungen
EP3735260A4 (de) Therapeutische peptide und verfahren zur behandlung von autoimmunerkrankungen
EP3791869A4 (de) Pharmazeutische zusammensetzung zur vorbeugung oder behandlung neurodegenerativer erkrankungen mit cox2-acetylierungsmittel als wirkstoff
EP3591039A4 (de) Verfahren zur isolierung von dopaminneuronen und pharmazeutische zusammensetzung zur behandlung von morbus parkinson unter verwendung desselben verfahrens isolierten dopaminneuronen
EP4255385A4 (de) Antigenzusammensetzung(en) und verfahren(en) gegen porphyromonas gingivalis zur prävention und/oder behandlung von infektionen und/oder erkrankungen
EP4098262A4 (de) Pharmazeutische zusammensetzung zur vorbeugung oder behandlung von diabetes und damit verbundenen stoffwechselerkrankungen
EP4351547A4 (de) Verbindungen, zusammensetzungen und verfahren zur prävention und/oder behandlung verschiedener mitochondrialer erkrankungen oder störungen, einschliesslich friedreich-ataxie
EP4043012A4 (de) Arzneimittel zum behandeln von arterienkrankheiten und verwendung davon
EP3919052A4 (de) Pharmazeutische zusammensetzung zur intraokularen oder oralen verabreichung zur behandlung von retinaerkrankungen
EP4438048A4 (de) Pharmazeutische zusammensetzung zur behandlung oder prävention von t-zell-bedingten erkrankungen
EP3932486A4 (de) Zusammensetzung zur behandlung von blutgerinnungs- und/oder komplementstörungen
EP3766503A4 (de) Verwendung eines mikrorna-210-inhibitors zur herstellung von arzneimitteln zur behandlung entzündlicher hauterkrankungen
EP3639854A4 (de) Mtor-hemmendes arzneimittel zur behandlung oder prävention von ophthalmischen symptomen, störungen oder erkrankungen und anwendung davon
EP3928785A4 (de) Arzneimittel und nahrungsmittel zur vorbeugung oder behandlung der durch das neuartige coronavirus verursachten pneumonie covid-19 und ihre verwendung
EP4375298A4 (de) Pharmazeutische zusammensetzung aus anti-angptl3-antikörper oder antigenbindendem fragment davon und deren anwendung
EP4495135A4 (de) Pharmazeutische verwendung von polypeptiden zur herstellung von arzneimitteln zur behandlung und/oder prävention von diabetes und adipositas und verwandten erkrankungen davon
EP3476401A4 (de) Zelltodinduzierer, zellproliferationshemmer und pharmazeutische zusammensetzung zur behandlung einer krankheit im zusammenhang mit abnormaler zellproliferation
EP4247415A4 (de) Pharmazeutische zusammensetzung zur behandlung von lebererkrankungen mit ssu72
MA52748A (fr) Produit immunogène comprenant il-4 et/ou il-13 pour le traitement de troubles associés à l&#39;expression ou à l&#39;activité aberrante de l&#39;il-4 et/ou de l&#39;il-13

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220829

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20240129

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 3/06 20060101ALI20240123BHEP

Ipc: A61P 3/04 20060101ALI20240123BHEP

Ipc: A61K 31/495 20060101ALI20240123BHEP

Ipc: A61K 31/4985 20060101ALI20240123BHEP

Ipc: A61K 31/506 20060101AFI20240123BHEP